Vaccines and Immunization
Vaccines are the single most cost-effective medical intervention ever devised, credited with the eradication of smallpox, the near-elimination of polio, and the prevention of an estimated four to five million deaths every year. At their heart is a beautifully simple idea: teach the immune system to recognise a dangerous pathogen before the real infection arrives, so that when it does, the body responds with the speed and precision of a veteran rather than the fumbling of a novice. Understanding how that training happens — and where the idea came from — turns vaccination from a list of injections into a coherent story about immunological memory.
This page connects the cellular immunology you learn in the lab to the schedules and public-health strategy you will apply in clinic. It matters because you will spend a career counselling patients, correcting misconceptions, and making judgement calls about who to protect and when.
Learning Objectives
- Explain how vaccines generate protective immunity through B-cell and T-cell memory
- Classify the major vaccine types (live-attenuated, inactivated, subunit, toxoid, mRNA, viral-vector) and their trade-offs
- Interpret the logic behind childhood and adult immunization schedules, including priming and boosting
- Define herd immunity and calculate the herd immunity threshold from R0
- Trace the historical arc from Jenner's 1796 experiment to modern mRNA platforms
- Recognise contraindications, adverse events, and common patient misconceptions
Quick Answer
A vaccine exposes the immune system to a harmless piece or form of a pathogen (an antigen), triggering an adaptive immune response that produces memory B cells and memory T cells without causing disease. On later exposure to the real pathogen, these memory cells mount a faster, stronger secondary response that neutralises the threat before illness develops. Vaccines come in several types — live-attenuated, inactivated, subunit/conjugate, toxoid, viral-vector, and mRNA — each balancing potency, safety, and stability differently. Multi-dose schedules exploit priming and boosting to build durable, high-affinity antibodies. When enough of a population is immune, transmission chains break down, protecting even the unvaccinated through herd immunity. The field began with Edward Jenner's cowpox experiment in 1796 and now spans genetically engineered mRNA vaccines developed within a year of a pandemic emerging.
Where It Came From
The need was ancient and desperate: infectious disease was, for most of human history, the leading cause of death. Smallpox alone killed an estimated 300 to 500 million people in the twentieth century before its eradication. Long before germ theory, people noticed that survivors of smallpox never caught it twice. This observation drove variolation — deliberately inoculating healthy people with material from smallpox pustules — practised in China, India, and the Ottoman Empire for centuries. Lady Mary Wortley Montagu introduced it to England in the 1720s. Variolation worked but was dangerous: roughly 1 to 2 percent of those inoculated died.
The decisive breakthrough came in 1796, when the English physician Edward Jenner tested a piece of rural folklore — that milkmaids who caught the mild cowpox seemed immune to smallpox. He inoculated an eight-year-old boy, James Phipps, with material from a milkmaid's cowpox lesion, then later challenged him with smallpox. The boy did not fall ill. Jenner coined the term vaccine from vacca, Latin for cow. He had no idea why it worked — immunology as a science did not yet exist — but he had proven that a safe surrogate could confer protection.
The mechanistic understanding arrived with Louis Pasteur in the 1880s, who deliberately weakened (attenuated) pathogens to make vaccines for chicken cholera, anthrax, and rabies, and generalised Jenner's principle. The twentieth century industrialised the field: toxoids for diphtheria and tetanus (1920s), the Salk (inactivated, 1955) and Sabin (oral live, 1961) polio vaccines, and the measles vaccine (1963). Genetic engineering brought the recombinant hepatitis B subunit vaccine (1986). Finally, decades of quiet work by Katalin Karikó and Drew Weissman on modified mRNA — long dismissed and underfunded — enabled the COVID-19 mRNA vaccines of 2020, developed at unprecedented speed and earning them the 2023 Nobel Prize in Medicine. Each step answered the same enduring need: protection without paying the price of natural infection.
How Vaccines Train the Immune System
To understand vaccines you must understand the difference between the primary and secondary immune responses. When the body first meets an antigen, naive B and T lymphocytes must find the rare cell whose receptor happens to match, activate, and proliferate. This takes seven to fourteen days — long enough for many pathogens to cause serious disease. The antibodies produced are initially low-affinity IgM.
A vaccine safely drives this primary response and, crucially, leaves behind two populations of long-lived cells:
- Memory B cells, which have already undergone class-switching (to IgG) and affinity maturation, so they produce better antibodies faster.
- Memory T cells, including helper (CD4+) cells that coordinate the response and cytotoxic (CD8+) cells that kill infected cells.
On real exposure, the secondary response is faster (days, not weeks), larger in magnitude, and produces high-affinity IgG and IgA. This is why a vaccinated person may still be infected but clears the pathogen before serious illness — vaccines often prevent disease more reliably than they prevent all infection.
Most vaccines also contain adjuvants (such as aluminium salts) that create local "danger signals," stimulating innate immunity and dramatically improving the adaptive response. Live vaccines rarely need adjuvants because the replicating organism supplies its own danger signals.
A worked example: tetanus
Clostridium tetani produces a toxin, not an invasive infection, and the disease itself does not reliably induce immunity — survivors can get tetanus again. The tetanus toxoid vaccine solves this by presenting a chemically inactivated toxin. A primary series of three doses builds memory; because antibody titres wane over about ten years, a booster is recommended every ten years, or after a dirty wound if the last dose was more than five years ago. This illustrates the whole logic: prime, remember, boost.
Types of Vaccines
| Type | How it works | Examples | Trade-offs |
|---|---|---|---|
| Live-attenuated | Weakened live pathogen replicates mildly | MMR, BCG, oral polio (OPV), varicella, yellow fever | Strong, durable, often lifelong immunity; risk in immunocompromised and pregnancy; needs cold chain |
| Inactivated (killed) | Whole pathogen killed by heat or chemicals | Inactivated polio (IPV), hepatitis A, rabies, whole-cell pertussis | Very safe; weaker response, needs boosters and adjuvant |
| Subunit / conjugate | Purified protein or polysaccharide, sometimes linked to a carrier protein | Hepatitis B, HPV, acellular pertussis, Hib, pneumococcal conjugate | Very safe and pure; conjugation needed for infants to respond to polysaccharides |
| Toxoid | Inactivated bacterial toxin | Tetanus, diphtheria | Targets toxin not organism; needs boosters |
| Viral-vector | Harmless virus delivers pathogen gene | Some COVID-19 (AstraZeneca, J&J), Ebola | Strong T-cell response; pre-existing immunity to vector can blunt it |
| mRNA | Lipid nanoparticle delivers mRNA; host cells make the antigen | COVID-19 (Pfizer, Moderna) | Fast to design, no live pathogen; requires cold storage, newer platform |
A key immunological subtlety explains conjugate vaccines. Infants under two respond poorly to pure polysaccharide antigens (a T-cell-independent response). Linking the polysaccharide to a protein carrier recruits T-cell help, producing robust, memory-forming immunity. This innovation made the Hib and pneumococcal vaccines effective in the age group that needs them most.
Immunization Schedules and Herd Immunity
Schedules are not arbitrary. They are engineered around three constraints: when maternal antibodies wane (they interfere with vaccine response, so live measles vaccine is given around 9–12 months), when a child is most vulnerable to a disease, and the need to space doses for optimal priming and boosting. A typical infant schedule includes BCG and hepatitis B at birth; DTP/DTaP, polio, Hib, pneumococcal, and rotavirus in the first six months; and MMR and varicella around the first birthday.
Herd immunity (community immunity) is the phenomenon whereby, once a sufficient fraction of a population is immune, an infected person cannot on average find enough susceptible contacts to sustain transmission, so outbreaks fizzle out — protecting infants too young to be vaccinated, the immunocompromised, and vaccine non-responders.
The threshold depends on how contagious the disease is, captured by the basic reproduction number R0 (the average number of new cases one case generates in a fully susceptible population). The herd immunity threshold is:
Threshold = 1 − (1 / R0)
For measles, one of the most contagious diseases known, R0 is roughly 12–18, giving a threshold around 92–95 percent. This is why measles returns quickly when coverage dips even slightly. For a disease with R0 of 3, only about 67 percent immunity is needed. Herd immunity does not apply to diseases like tetanus, whose source is the environment (soil) rather than person-to-person spread — hence everyone must be individually protected.
Real-World Applications
- Clinical counselling: Explaining to a parent why the MMR is delayed to age one (maternal antibody interference), or why a second dose is needed (to catch the ~5 percent who did not respond to the first), turns compliance from an order into an informed choice.
- Travel and occupational medicine: Advising yellow fever vaccination before travel to endemic zones, or hepatitis B and rabies pre-exposure prophylaxis for healthcare and laboratory workers.
- Outbreak control: Ring vaccination — vaccinating the contacts of contacts around a case — was the strategy that finished smallpox eradication and was used against Ebola.
- Protecting the vulnerable: Vaccinating pregnant women against pertussis and influenza passes protective antibodies to the newborn (passive immunity), and vaccinating household contacts (cocooning) shields those who cannot be vaccinated.
Common Mistakes
-
"Vaccines give you the disease they prevent." Wrong for essentially all vaccines. Inactivated, subunit, toxoid, and mRNA vaccines contain no live pathogen and cannot cause the disease. Live-attenuated vaccines can rarely cause a mild form in severely immunocompromised people, which is exactly why they are contraindicated there — but a healthy person's fever after MMR is the immune response, not measles.
-
"Natural immunity is always better, so infection is preferable." While natural infection can induce strong immunity, it exacts the price of the disease itself — which can mean measles encephalitis, congenital rubella, HPV-driven cancer, or death. Some vaccines (tetanus, HPV) even produce better protection than natural infection.
-
"If everyone else is vaccinated, my child doesn't need it." This free-rider logic collapses when many families adopt it. Herd immunity requires a high threshold; falling below it (as with measles at 95 percent) restarts outbreaks. Relying on others also offers no protection if your child is exposed while coverage is already eroding.
-
"A minor cold means we must postpone the vaccine." Mild illness with or without low-grade fever is not a contraindication. Unnecessary deferral leaves children unprotected and is a common cause of missed doses.
Comparison and Connections
| Concept | Active immunity | Passive immunity |
|---|---|---|
| Source | Own immune system makes response | Pre-formed antibodies given |
| Examples | Vaccines, natural infection | Maternal IgG, antitoxin, monoclonal antibodies, immunoglobulin |
| Onset | Slow (days to weeks) | Immediate |
| Duration | Long, often years to life | Short (weeks to months) |
| Memory | Yes | No |
Vaccines produce active immunity. Contrast this with passive immunity — the transfer of ready-made antibodies (e.g. tetanus immunoglobulin after a wound, or rabies immunoglobulin), which acts instantly but fades and leaves no memory. In practice the two are combined: a serious dirty wound in an under-vaccinated patient gets both the toxoid (active) and immunoglobulin (passive) for immediate plus lasting protection. These ideas build directly on adaptive immunity and immunological memory.
Practice Questions
Recall
Q: Name the six main categories of vaccine by mechanism. A: Live-attenuated, inactivated (killed), subunit/conjugate, toxoid, viral-vector, and mRNA.
Understanding
Q: Why do polysaccharide antigens need to be conjugated to a protein to work in infants? A: Pure polysaccharides trigger a T-cell-independent response, which infants under two mount poorly and which forms little memory. Linking the polysaccharide to a carrier protein recruits T-helper cells, generating a strong, memory-forming (T-cell-dependent) response.
Application
Q: A disease has an R0 of 5. What proportion of the population must be immune to achieve herd immunity? A: Threshold = 1 − (1/5) = 1 − 0.2 = 0.8, so about 80 percent must be immune.
Analysis
Q: Why does measles resurge so readily compared with a disease like polio when vaccination rates fall by the same amount? A: Measles has an extremely high R0 (~12–18), so its herd immunity threshold is very high (~95 percent). Even a small drop in coverage pushes the susceptible fraction above the critical level, letting transmission chains re-establish. Polio's lower R0 gives a lower threshold and more tolerance for coverage gaps.
FAQ
Why do some vaccines need boosters and others don't? It depends on how durable the memory is. Live-attenuated vaccines (MMR) often give lifelong immunity because the mild replication mimics real infection. Inactivated and toxoid vaccines produce weaker, waning responses, so periodic boosters restimulate memory cells and raise antibody titres.
Can I get the flu from the flu vaccine? No. The injected influenza vaccine is inactivated or a subunit and contains no live virus. Post-vaccination aches or low fever are the immune response ramping up, not infection.
Are vaccines linked to autism? No. The original 1998 study claiming a link was fraudulent, retracted, and its author lost his medical licence. Numerous large studies across millions of children have found no association. This is one of the most thoroughly disproven claims in medicine.
Why can't pregnant women or immunocompromised people get live vaccines? Live-attenuated organisms replicate, and in someone with a weakened or altered immune system they can occasionally cause disease or harm the fetus. Inactivated, subunit, and toxoid vaccines are generally safe and often recommended in these groups.
How were COVID-19 mRNA vaccines developed so fast if they're safe? Speed came from prior investment: decades of mRNA research, existing lipid-nanoparticle technology, huge parallel funding, and overlapping trial phases — not skipped safety steps. Tens of thousands of participants were monitored before approval, and billions of doses have since been given under continued surveillance.
Quick Revision
- Vaccines create memory B and T cells so the secondary response is faster and stronger.
- Six types: live-attenuated, inactivated, subunit/conjugate, toxoid, viral-vector, mRNA.
- Conjugation adds T-cell help so infants respond to polysaccharide antigens.
- Adjuvants boost innate signals and improve the response of non-live vaccines.
- Herd immunity threshold = 1 − (1/R0); measles needs ~95 percent, hence its fragility.
- Active immunity (vaccines) is slow but lasting; passive immunity (antibodies) is instant but temporary.
- History: Jenner 1796 (cowpox) → Pasteur attenuation 1880s → toxoids, polio, measles → recombinant hepatitis B → mRNA (2020, Nobel 2023).
- Mild illness is not a contraindication; live vaccines are contraindicated in pregnancy and immunocompromise.
Related Topics
Prerequisites
- Immunology overview
- Adaptive immunity, B cells, T cells, and antibodies (see the immunology branch)
Related Topics
Next Topics
- Pediatrics and childhood immunization
- Hypersensitivity and vaccine adverse reactions (see the immunology branch)